Liminatus Pharma: Funding, Investors & Team (Sep 2026)
Liminatus Pharma is a clinical-stage biopharmaceutical company that specializes in developing immune-modulating cancer therapies. Its pipeline includes a humanized anti-CD47 monoclonal antibody (IBA101) targeting advanced solid tumors, a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II trials for gastrointestinal cancers, and a GCC-targeted CAR-T cell therapy. The company also holds exclusive rights to the YN1203 companion diagnostic for checkpoint inhibitor therapies.
Liminatus Pharma has raised $1.9M across 1 funding round on record, the most recent an undisclosed round of $1.9M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Liminatus Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Liminatus Pharma Funding Rounds
Liminatus Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Liminatus Pharma Funding Compared to Other Biotechnology Startups
Liminatus Pharma's latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Liminatus Pharma in Biotechnology and Wilmington
Companies Similar to Liminatus Pharma
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Liminatus Pharma Funding FAQs
What does Liminatus Pharma do?
Liminatus Pharma is a clinical-stage biopharmaceutical company that specializes in developing immune-modulating cancer therapies. Its pipeline includes a humanized anti-CD47 monoclonal antibody (IBA101) targeting advanced solid tumors, a Guanylyl Cyclase C (GCC) cancer vaccine in Phase II trials for gastrointestinal cancers, and a GCC-targeted CAR-T cell therapy. The company also holds exclusive rights to the YN1203 companion diagnostic for checkpoint inhibitor therapies.
How much funding has Liminatus Pharma raised?
Liminatus Pharma has raised $1.9M across 1 round on record. The most recent is an undisclosed round of $1.9M announced in Jun 2026.
When did Liminatus Pharma last raise funding?
Liminatus Pharma's most recent funding round on record is an undisclosed round of $1.9M, announced in Jun 2026.
Who founded Liminatus Pharma?
FundedIQ lists Chris Kim (Founder) at Liminatus Pharma.
Where is Liminatus Pharma headquartered?
Liminatus Pharma is based in Wilmington, Delaware, United States.
How many employees does Liminatus Pharma have?
Liminatus Pharma is in the 1-10 employee band.
How does Liminatus Pharma's funding compare to other Biotechnology startups?
Liminatus Pharma's latest round of $1.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Liminatus Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Liminatus Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.